Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words 'Allain, H' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 104 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Allain, H; Arbus, L; Schuck, S
      Efficacy and safety of zolpidem administered - 'As needed' in primary insomnia results of a double-blind, placebo-controlled study

      CLINICAL DRUG INVESTIGATION
    2. Bentue-Ferrer, D; Reymann, JM; Tribut, O; Allain, H; Vasar, E; Bourin, M
      Role of dopaminergic and serotonergic systems on behavioral stimulatory effects of low-dose alprazolam and lorazepam

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    3. Heun, R; Rosler, M; Allain, H
      Tiapride in gerontopsychiatry

      EUROPEAN PSYCHIATRY
    4. Allain, H; Schuck, S; Mauduit, N; Djemai, M
      Comparative effects of pharmacotherapy on the maintenance of cognitive function

      EUROPEAN PSYCHIATRY
    5. Robert, PH; Allain, H
      Clinical management of agitation in the elderly with tiapride

      EUROPEAN PSYCHIATRY
    6. Allain, H; Galesne, G; Fresnel, A; Tribut, O; Le Duff, F; Schuck, S; Le Cavorzin, P; Mauduit, N; Le Beux, P
      Teaching pharmacology on the internet: a university experience

      PRESSE MEDICALE
    7. Le Cavorzin, P; Poudens, SA; Chagneau, F; Carrault, G; Allain, H; Rochcongar, P
      A comprehensive model of spastic hypertonia derived from the pendulum testof the leg

      MUSCLE & NERVE
    8. Biraben, A; Allain, H; Scarabin, JM; Schuck, S; Edan, G
      Exacerbation of juvenile myoclonic epilepsy with lamotrigine - Reply from the authors

      NEUROLOGY
    9. Allain, H; Schuck, S; Bentue-Ferrer, D; Bourin, M; Vercelletto, M; Reymann, JM; Polard, E
      Anxiolytics in the treatment of behavioral and psychological symptoms of dementia

      INTERNATIONAL PSYCHOGERIATRICS
    10. Allain, H; Schuck, S; Mauduit, N
      Depression in Parkinson's disease - Must be properly diagnosis and treatedto avoid serious morbidity

      BRITISH MEDICAL JOURNAL
    11. Patat, A; Rosenzweig, P; Enslen, M; Trocherie, S; Miget, N; Bozon, MC; Allain, H; Gandon, JM
      Effects of a new slow release formulation of caffeine on EEG, psychomotor and cognitive functions in sleep-deprived subjects

      HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
    12. Schuck, S; Allain, H; Lebeux, P; Chaperon, J
      Antidepressant prescription practices in a population of hospital psychiatrists and non-psychiatrists

      PRESSE MEDICALE
    13. Allain, H; Schuck, S; Mauduit, N; Djemai-Zegloche, M; Geffroy, M; Chaperon, J
      Psychiatries and clinical research - A dialogue with hospital directors

      PRESSE MEDICALE
    14. Zoghlache, MD; Burger, K; Schuck, S; Moller, HJ; Rapoport, SI; Allain, H; Hampel, H
      Multiconceptual therapy in Alzheimer's disease

      PRESSE MEDICALE
    15. Allain, H; Schuck, S; Mauduit, N; Saiag, B; Pinel, JF; Bentue-Ferrer, D
      The pathophysiology of migraine.

      PATHOLOGIE BIOLOGIE
    16. Mauduit, N; Schuck, S; Allain, H; Chaperon, J
      Rating scales and questionnaires in Parkinson's disease

      REVUE NEUROLOGIQUE
    17. Biraben, A; Allain, H; Scarabin, JM; Schuck, S; Edan, G
      Exacerbation of juvenile myoclonic epilepsy with lamotrigine

      NEUROLOGY
    18. Allain, H; Destee, A; Petit, H; Patay, M; Schuck, S; Bentue-Ferrer, D; Le Cavorzin, P
      Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease

      EUROPEAN NEUROLOGY
    19. Allain, H; Dautzenberg, PHJ; Maurer, K; Schuck, S; Bonhomme, D; Gerard, D
      Double blind study of tiapride versus haloperidol and placebo in agitationand aggressiveness in elderly patients with cognitive impairment

      PSYCHOPHARMACOLOGY
    20. Allain, H; Schuck, S; Lebreton, S; Strenge-Hesse, A; Braun, W; Gandon, JM; Brissot, P
      Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease

      DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
    21. Thomas-Ollivier, V; Reymann, JM; Le Moal, S; Schuck, S; Lieury, A; Allain, H
      Procedural memory in recent-onset Parkinson's disease

      DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
    22. Allain, H; Bourin, M; Reymann, JM; Bentue-Ferrer, D; Patat, A; Schuck, S; Lieury, A
      Emotion, anxiolysis and memory

      HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
    23. Agid, Y; Destee, A; Durif, F; Montastruc, JL; Pedarriosse, AM; Deptula, D; Hoffman-La Roche, F; Pollak, P; Bonnet, AM; Allain, H; le Cavorzin, P; Barroche, G; Blin, O; Cesaro, P; Chazot, G; Broussolle, E; Leduc, V; Debilly, B; Feve, JR; Geraud, G; Fabre, N; Gu, C; Gil, R; Henry, P; Tison, F; Ansquer, O; Brefel, C; Payen, I; Said, G; Plante, V; Touchon, J; Cesari, JB; Camu, W; Bennys, K; Viallet, F; Warter, JM; Tranchant, C; Ziegler, M
      Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients

      MOVEMENT DISORDERS
    24. Patat, A; Rosenzweig, P; Miget, N; Allain, H; Gandon, JM
      Effects of 50mg amisulpride on EEG, psychomotor and cognitive functions inhealthy sleep-deprived subjects

      FUNDAMENTAL & CLINICAL PHARMACOLOGY
    25. Patat, A; Chaufour, S; Gandon, JM; Allain, H; Rosenzweig, P
      Safety and pharmacodynamics of single ascending doses of SL34.0026, a new reversible and selective MAO-B inhibitor in healthy subjects

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    26. Patat, A; Alberini, H; Bonhomme, D; Soubrane, C; Allain, H; Gandon, JM
      Effects of tiapride on electroencephalograms and cognitive functions in the elderly

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    27. Pollak, P; Destee, A; Lille, CHU; Tison, F; Pere, JJ; Malmaison, R; Bordeix, I; Agid, Y; Allain, H; Borg, M; Broussolle, E; Durif, F; Geny, C; Prunier-Levilon, C; Bretonneau, CHU; Rascol, O; Sangla, S; Verin, M; Viallet, F; Tranchant, C
      Clozapine in drug-induced psychosis in Parkinson's disease

      LANCET
    28. Schuck, S; Bentue-Ferrer, D; Beaufils, C; Polard, E; Belliard, S; Allain, H
      Side-effects and drugs for Alzheimer's disease

      THERAPIE
    29. Allain, H; Bentue-Ferrer, D; Schuck, S; Ruffault, A
      beta interferons in multiple sclerosis: pharmacological differences.

      REVUE NEUROLOGIQUE
    30. Shalev, M; Staerman, F; Allain, H; Lobel, B; Saiag, B
      Stimulation of P2y purinoceptors induces, via nitric oxide production, endothelium-dependent relaxation of human isolated corpus cavernosum

      JOURNAL OF UROLOGY
    31. Siproudhis, L; Bellissant, E; Juguet, F; Allain, H; Bretagne, JF; Gosselin, M
      Perception of and adaptation to rectal isobaric distension in patients with faecal incontinence

      GUT
    32. Saiag, B; Shacoori, V; Bodin, P; Pape, D; Allain, H; Burnstock, G
      Free radical involvement in endothelium-dependent responses of the rat thoracic aorta in moderate hypoxic conditions

      EUROPEAN JOURNAL OF PHARMACOLOGY
    33. Siproudhis, L; Bellissant, E; Pagenault, M; Mendler, MH; Allain, H; Bretagne, JF; Gosselin, M
      Fecal incontinence with normal anal canal pressures: Where is the pitfall?

      AMERICAN JOURNAL OF GASTROENTEROLOGY
    34. Allain, H; Le Coz, F; Borderies, P; Schuck, S; de La Giclais, B; Patat, A; Gandon, JM
      Use of zolpidem 10 mg as a benzodiazepine substitute in 84 patients with insomnia

      HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
    35. SCHUCK S; ALLAIN H; GANDON JM; PATAT A; MILLET V; LECOZ F
      EFFECT OF BROMAZEPAM VERSUS PLACEBO ON INHIBITION AND WAITING CAPACITY IN YOUNG-WOMEN WITH TRAITS OF ANXIETY

      Fundamental and clinical pharmacology
    36. ALLAIN H; BENTUEFERRER D; ZEKRI O; SCHUCK S; LEBRETON S; REYMANN JM
      EXPERIMENTAL AND CLINICAL METHODS IN THE DEVELOPMENT OF ANTI-ALZHEIMER DRUGS

      Fundamental and clinical pharmacology
    37. ALLAIN PY; SCHUCK S; BEAUFILS C; ZEKRI O; GANILSY M; ALLAIN H
      DRUGS ON INTERNET - WHATS AT STAKE FOR PU BLIC-HEALTH

      La Presse medicale
    38. SIPROUDHIS L; MAHMOUD H; BRIAND N; JUGUET F; BRETAGNE JF; ALLAIN H; GOSSELIN M
      CAUSAL ASSESSMENT OF DRUG-INDUCED ACUTE COLITIS - A PROSPECTIVE-STUDYOF 58 CONSECUTIVE CASES

      Gastroenterologie clinique et biologique
    39. SIPROUDHIS L; BELLISSANT E; JUGUET F; ALLAIN H; BRETAGNE JF; GOSSELIN M
      EFFECTS OF CHOLINERGIC AGENTS ON ANORECTAL PHYSIOLOGY

      Alimentary pharmacology & therapeutics
    40. DENOLLE T; SASSANO P; PATAT A; LEBRETON S; ALLAIN H; GANDON JM
      EFFECTS OF NICARDIPINE AND CLONIDINE ON COGNITIVE FUNCTIONS AND EEG IN MIDDLE-AGED AND ELDERLY HYPERTENSIVE PATIENTS

      Journal of hypertension
    41. PATAT A; TROY S; BURKE J; TROCHERIE S; DANJOU P; LECOZ F; ALLAIN H; GANDON JA
      ABSOLUTE BIOAVAILABILITY AND ELECTROENCEPHALOGRAPHIC EFFECTS OF CONVENTIONAL AND EXTENDED-RELEASE FORMULATIONS OF VENLAFAXINE IN HEALTHY-SUBJECTS

      Journal of clinical pharmacology
    42. ESTADIEU MC; MACHOU C; BERTHEZENE P; PASTOR MJ; ANGELINI B; BOHOR M; BONGRAND MC; TIMONDAVID P; GASTAUT JL; ALLAIN H; MICHEL BF
      TOLERANCE-EFFICACY OUTCOME OF ONE-YEAR OF TACRINE UTILIZATION IN 100 ALZHEIMERS-DISEASE CASES

      Therapie
    43. ALLAIN H; BENTUEFERRER D
      CLINICAL EFFICACY OF ALMITRINE-RAUBASINE - AN OVERVIEW

      European neurology
    44. BENTUEFERRER D; REYMANN JM; ROUSSELLE JC; MASSOT O; BOURIN M; ALLAIN H; FILLION G
      5-HT-MODULINE, A 5-HT1B 1D RECEPTOR ENDOGENOUS MODULATOR, INTERACTS WITH DOPAMINE RELEASE MEASURED IN-VIVO BY MICRODIALYSIS/

      European journal of pharmacology
    45. ONEILL MJ; HICKS CA; WARD MA; CARDWELL GP; REYMANN JM; ALLAIN H; BENTUEFERRER D
      DOPAMINE D-2 RECEPTOR AGONISTS PROTECT AGAINST ISCHEMIA-INDUCED HIPPOCAMPAL NEURODEGENERATION IN GLOBAL CEREBRAL-ISCHEMIA

      European journal of pharmacology
    46. SIPROUDHIS L; BELLISSANT E; JUGUET P; ALLAIN H; BRETAGNE JF; GOSSELIN M
      OCTREOTIDE ACTS ON ANORECTAL PHYSIOLOGY - A DYNAMIC STUDY IN HEALTHY-SUBJECTS

      Clinical pharmacology and therapeutics
    47. ROSENZWEIG P; PATAT A; ZIELENIUK I; CIMAROSTI I; ALLAIN H; GANDON JM
      COGNITIVE PERFORMANCE IN ELDERLY SUBJECTS AFTER A SINGLE-DOSE OF BEFLOXATONE, A NEW REVERSIBLE SELECTIVE MONOAMINE-OXIDASE-A INHIBITOR

      Clinical pharmacology and therapeutics
    48. SIPROUDHIS L; BELLISSANT E; JUGUET F; MENDLER MH; ALLAIN H; BRETAGNE JF; GOSSELIN M
      RECTAL ADAPTATION TO DISTENSION IN PATIENTS WITH OVERT RECTAL PROLAPSE

      British Journal of Surgery
    49. ALLAIN H; MONTI J
      GENERAL SAFETY PROFILE OF ZOLPIDEM - SAFETY IN ELDERLY, OVERDOSE AND REBOUND EFFECTS

      European psychiatry
    50. PATAT A; DUBRUC C; DESCHAMP C; DURRIEU G; TROCHERIE S; CIMAROSTI I; ALLAIN H; ROSENZWEIG P; GANDON JM
      EEG, MAO-A INHIBITION, PHARMACOKINETICS AND SAFETY OF BEFLOXATONE IN THE ELDERLY

      Human psychopharmacology
    51. PAPE D; BEUCHARD J; GUILLO P; ALLAIN H; BELLISSANT E
      HYPOXIC CONTRACTILE RESPONSE IN ISOLATED RAT THORACIC AORTA - ROLE OFENDOTHELIUM, EXTRACELLULAR CALCIUM AND ENDOTHELIN

      Fundamental and clinical pharmacology
    52. ALLAIN H; BENTUEFERRER D
      INTERROGATIONS AND SOLUTIONS CONCERNING PARKINSONS-DISEASE

      La Presse medicale
    53. ALLAIN H; BENTUEFERRER D; GANDON JM; LEDOZE F; BELLIARD S
      DRUGS USED IN ALZHEIMERS-DISEASE AND NEUROPLASTICITY

      Clinical therapeutics
    54. THAMINY S; REYMANN JM; HERESBACH N; ALLAIN H; LECHAT P; BENTUEFERRER D
      IS CHLORMETHIAZOLE NEUROPROTECTIVE IN EXPERIMENTAL GLOBAL CEREBRAL-ISCHEMIA - A MICRODIALYSIS AND BEHAVIORAL-STUDY

      Pharmacology, biochemistry and behavior
    55. ALLAIN H; BAUDOIN V; DUBOIS B; FORETTE F
      THE PLACE OF CLINICAL-TRIALS IN MEMORY CL INICS

      Therapie
    56. ALLAIN H; ZEKRI O; FENELON G; SCHUCK S; BENTUEFERRER D
      NEUROTRANSMISSION AND HUNTINGTONS-DISEASE

      La Semaine des hopitaux de Paris
    57. RINNE UK; BRACCO F; CHOUZA C; DUPONT E; GERSHANIK O; MASSO JFM; MONTASTRUC JL; MARSDEN CD; DUBINI A; ORLANDO N; GRIMALDI R; BERGAMASCO B; MAMOLI A; SCARPA M; SCARANO M; CANAL N; FRANCESCHI M; ALBANESE A; BENTIVOGLIO AR; BARONE P; CICARELLI G; MALESANI R; MICHELI F; MUCHNIK S; PLIEGO L; SOMOZA M; GORI HE; DOMINGUEZ R; FAMULARI A; ALJANATI R; MIKKELSEN B; OLIVE JM; BURGUERA J; MIQUEL F; GIMENEZROLDAN S; MATEO D; ALLAIN H; VERIN M; DEGOS JD; DESTEE A; WARTER JM; BERNARDI F; CHILLOTTI C; SERRA JP; GARRIGA MC; BENECKE R; PIROTTA RMN; GROSSONI M
      CABERGOLINE IN THE TREATMENT OF EARLY PARKINSONS-DISEASE - RESULTS OFTHE FIRST YEAR OF TREATMENT IN A DOUBLE-BLIND COMPARISON OF CABERGOLINE AND LEVODOPA

      Neurology
    58. PATAT A; TROCHERIE S; LECOZ F; TROY S; BURKE J; DANJOU P; ALLAIN H; GANDON JM
      ABSOLUTE BIOAVAILABILITY AND EEG EFFECTS OF CT AND ER VENLAFAXINE FORMULATION

      Clinical pharmacology and therapeutics
    59. LABLANCHE JM; GROLLIER G; LUSSON JR; BASSAND JP; DROBINSKI G; BERTRAND B; BATTAGLIA S; DESVEAUX B; JUILLIERE Y; JULIARD JM; METZGER JP; COSTE P; QUIRET JC; DUBOISRANDE JL; CROCHET PD; LETAC B; BOSCHAT J; VIROT P; FINET G; LEBRETON H; LIVAREK B; LECLERCQ F; BEARD T; GIRAUD T; MCFADDEN EP; BERTRAND ME; DUPUIS B; ALLAIN H; BAUTERS C; KOLSKY H; LENDRESSE P; REGLIER JC; KABIR M; LEMAIRE JC; RIOU MD; TESSIER P; POTIER JC; BARRAUD P; SCHIELE F; MENEVEAU N; MONTALESCOT G; MACHECOURT J; GUERMONPREZ JL; QUILLIET L; MAILLARD L; DANCHIN N; CHERRIER F; STEG PG; HIMBERT D; VACHERON A; LEFEUVRE C; DOSSANTOS P; BESSE P; AVINEE P; CASTAIGNE A; APTECAR E; BAR O; KONING R; BAALA B; GILARD M; CORNEC P; DOUMEIX JJ; BENSAID J; BEAUNE J; ANDREFOUET X; LECLERC C; PONY JC; NORMAND JP; GROLLEAU R; CARRIE D; BERNADET P
      EFFECT OF THE DIRECT NITRIC-OXIDE DONORS LINSIDOMINE AND MOLSIDOMINE ON ANGIOGRAPHIC RESTENOSIS AFTER CORONARY BALLOON ANGIOPLASTY - THE ACCORD STUDY

      Circulation
    60. ALLAIN H; BENTUEFERRER D; REYMANN JM; ROUSSELLE JC; MASSOT O; BOURIN M; FILLION G
      DOES 5HT-MODULINE INTERACT WITH THE 5HT(1B) AGONIST CP 93,129-INDUCEDRELEASE OF STRIATAL DOPAMINE IN RATS

      British Journal of Pharmacology
    61. CALDWELL MA; REYMANN JM; ALLAIN H; LEONARD BE; BENTUEFERRER D
      LISURIDE PREVENTS LEARNING AND MEMORY IMPAIRMENT AND ATTENUATES THE INCREASE IN EXTRACELLULAR DOPAMINE-INDUCED BY TRANSIENT GLOBAL CEREBRAL-ISCHEMIA IN RATS

      Brain research
    62. ALLAIN H; NEUMAN E; MALBEZIN M; SALZMAN V; GUEZ D; WESNES K; GANDON JM
      BRIDGING STUDY OF S12024 IN 53 INPATIENTS WITH ALZHEIMERS-DISEASE

      Journal of the American Geriatrics Society
    63. LEMOAL S; REYMANN JM; THOMAS V; CATTENOZ C; LIEURY A; ALLAIN H
      EFFECT OF NORMAL AGING AND OF ALZHEIMERS-DISEASE ON EPISODIC MEMORY

      Dementia and geriatric cognitive disorders
    64. BENTUEFERRER D; MENARD G; ALLAIN H
      MONOAMINE-OXIDASE-B INHIBITORS - CURRENT STATUS AND FUTURE POTENTIAL

      CNS DRUGS
    65. PATAT A; CERCLE M; TROCHERIE S; PEYTAVIN G; POTIN C; ALLAIN H; GANDON JM
      LACK OF AMPHETAMINE-LIKE EFFECTS AFTER ADMINISTRATION OF MEFENOREX INNORMAL YOUNG SUBJECTS

      Human psychopharmacology
    66. ALLAIN H; LIEURY A; BELLIARD S; CALDWELL M; PATAT A; GANDON JM
      EFFECT OF DRUGS ON MNESTIC PERFORMANCE - A METHODOLOGICAL APPROACH

      Human psychopharmacology
    67. PAPE D; VERNILLET L; BELLISSANT E; BENTUEFERRER D; ALLAIN H
      NONINTERCHANGEABILITY OF SPECIFIC RADIOIMMUNOASSAY AND MONOCLONAL-ANTIBODY FLUORESCENT POLARIZATION IMMUNOASSAY IN CYCLOSPORINE MEASUREMENTS

      Fundamental and clinical pharmacology
    68. ALLAIN H; MARUELLE L; BENETON C; ROUAULT G; BELLIARD S
      ACUTE EPISODES OF HIGH BLOOD-PRESSURE IND UCED BY TACRINE

      La Presse medicale
    69. BEUCHARD J; ROCHCONGAR P; SAILLANT G; ALLAIN H; BENETON C
      PEFLOXACIN-INDUCED CHRONIC BILATERAL TEND INOPATHY OF THE ACHILLES-TENDON WITHOUT SPONTANEOUS RUPTURE, SURGICAL-TREATMENT

      La Presse medicale
    70. CALDWELL MA; REYMANN JM; BENTUEFERRER D; ALLAIN H; LEONARD BE
      THE DOPAMINE AGONISTS LISURIDE AND PIRIBEDIL PROTECT AGAINST BEHAVIORAL AND HISTOLOGICAL-CHANGES FOLLOWING 4-VESSEL OCCLUSION IN THE RAT

      Neuropsychobiology
    71. THOMAS V; REYMANN JM; LIEURY A; ALLAIN H
      ASSESSMENT OF PROCEDURAL MEMORY IN PARKINSONS-DISEASE

      Progress in neuro-psychopharmacology & biological psychiatry
    72. THAMINY S; BELLISSANT E; MAGINN M; DECOMBE R; BENTUEFERRER D; ALLAIN H; BENTUEFERRER D
      EFFECT OF BRAIN MICRODIALYSIS ON AMINERGIC TRANSMITTER LEVELS IN REPEATED CEREBRAL GLOBAL TRANSIENT ISCHEMIA IN RAT

      Journal of neuroscience methods
    73. LEMOINE P; ALLAIN H
      INDUCTION OF SLEEP - INTRODUCTION TO THE SYMPOSIUM

      Sleep
    74. PATAT A; LECOZ F; DUBRUC C; GANDON JM; DURRIEU G; CIMAROSTI I; JEZEQUEL S; CURET O; ZIELENIUK I; ALLAIN H; ROSENZWEIG P
      PHARMACODYNAMICS AND PHARMACOKINETICS OF 2 DOSE REGIMENS OF BEFLOXATONE, A NEW REVERSIBLE AND SELECTIVE MONOAMINE-OXIDASE INHIBITOR, AT STEADY-STATE IN HEALTHY-VOLUNTEERS

      Journal of clinical pharmacology
    75. LIEURY A; GERMAIN R; MENARD G; GANDON JM; ALLAIN H
      STUDY OF THE CORRELATIONS BETWEEN SELF-ES TIMATION OF MEMORY, A PSYCHOMETRIC TEST (SM9), AND A TEST OF MEMORY DAILY-LIFE EVENTS

      Therapie
    76. ALLAIN H; BELLIARD S; LIEURY A; MENARD G; PATAT A; LECOZ F; GANDON JM
      RANDOMIZED DOUBLE-BLIND-STUDY OF MINAPRIN E VERSUS PLACEBO ON MEMORY LOSS

      Therapie
    77. LECAVORZIN P; SARKIS S; BENETON C; PINEL JF; MARUELLE L; LEVAOU P; ALLAIN H
      SEROTONIN SYNDROME AND FLUVOXAMINE IN A P ARKINSONIAN PATIENT

      Therapie
    78. BEUCHARD J; BENETON C; ALLAIN H
      HOW DOES PHARMACOVIGILANCE WORK

      La Semaine des hopitaux de Paris
    79. BELLISSANT E; DENOLLE T; SINNASSAMY P; BICHET DG; GIUDICELLI JF; LECOZ F; GANDON JM; ALLAIN H
      SYSTEMIC AND REGIONAL HEMODYNAMIC AND BIOLOGICAL EFFECTS OF A NEW KAPPA-OPIOID AGONIST, NIRAVOLINE, IN HEALTHY-VOLUNTEERS

      The Journal of pharmacology and experimental therapeutics
    80. GANDON JM; LECOZ F; ENSLEN M; CHAUFFARD F; TACHON P; ALLAIN H; PATAT A
      DETERMINATION OF THE MAXIMAL TOLERATED DOSE OF A NEW ACUTE ORAL CAFFEINE FORMULATION IN HEALTHY-VOLUNTEERS

      Clinical pharmacology and therapeutics
    81. SAIAG B; HILLAIREBUYS D; CHAPAL J; PETIT P; PAPE D; RAUL B; ALLAIN H; LOUBATIERESMARIANI MM
      STUDY OF THE MECHANISMS INVOLVED IN ADENOSINE-5'-O-(2-THIODIPHOSPHATE) INDUCED RELAXATION OF RAT THORACIC AORTA AND PANCREATIC VASCULAR BED

      British Journal of Pharmacology
    82. ALLAIN H; LIEURY A; QUEMENER V; THOMAS V; REYMANN JM; GANDON JM
      PROCEDURAL MEMORY AND PARKINSONS-DISEASE

      Dementia
    83. ALLAIN H; PATAT A; LIEURY A; LECOZ F; JANUS C; MENARD G; GANDON JM
      COMPARATIVE-STUDY OF THE EFFECTS OF ZOPICLONE (7.5 MG), ZOLPIDEM, FLUNITRAZEPAM AND A PLACEBO ON NOCTURNAL COGNITIVE PERFORMANCE IN HEALTHY-SUBJECTS, IN RELATION TO PHARMACOKINETICS

      European psychiatry
    84. LEMOINE P; ALLAIN H; JANUS C; SUTET P
      GRADUAL WITHDRAWAL OF ZOPICLONE (7.5 MG) AND ZOLPIDEM (10 MG) IN INSOMNIACS TREATED FOR AT LEAST 3 MONTHS

      European psychiatry
    85. PATAT A; GANDON JM; DURRIEU G; LECOZ F; CURET O; CIMAROSTI I; ALLAIN H
      EFFECTS OF SINGLE AND MULTIPLE DOSES OF A NEW REVERSIBLE MAO-A INHIBITOR, BEFLOXATONE, ON PSYCHOMOTOR PERFORMANCE AND MEMORY IN HEALTHY-SUBJECTS

      Human psychopharmacology
    86. ALLAIN H; LIEURY A; THOMAS V; REYMANN JM; GANDON JM; BELLIARD S
      EXPLICIT AND PROCEDURAL MEMORY IN PARKINSONS-DISEASE

      Biomedicine & pharmacotherapy
    87. COGNEZ P; PAPE D; BURGOT G; ALLAIN H; BURGOT JL
      ELIMINATION OF LINEAR PARAMETERS IN NONLINEAR REGRESSIONS - A FAST AND EFFECTIVE METHOD FOR THE DETERMINATION OF BINDING PARAMETERS

      International journal of pharmaceutics
    88. BOURIN M; ALLAIN H; ATASSI G; BLANCHARD JC; BLIN O; BOST PE; BRAQUET P; CHAUMETRIFFAUD D; DANGUMAU J; ELIA AF; HOUDEBINE LM; LECHAT P; LECOMTE JM; LEFUR G; LEHNER JP; MARSAC J; PETIT P; SASSARD J; SYROTA A; VILAINE JP
      THE FUTURE OF PHARMACOLOGICAL MODELS

      Therapie
    89. BENETON C; CARLIER P; MASSON V; ALLAIN H
      AMINEPTINE (SURVECTOR(R)) ABUSE AND PREGN ANCY - A CASE-REPORT

      Therapie
    90. ONEILL M; ALLAIN H; BENTUEFERRER D; BELLISSANT E; DECERTAINES J; LEONARD BE
      PHARMACOLOGICAL STRATEGIES IN THE TREATMENT OF CEREBRAL-ISCHEMIA

      European neurology
    91. PATAT A; LECOZ F; GANDON JM; BECK A; DURRIEU G; CURET O; ALLAIN H
      USE OF FREE DHPG PLASMA-LEVELS TO ASSESS EQUIPOTENCY OF 2 DOSAGE REGIMENS OF BEFLOXATONE, A REVERSIBLE MAO-A INHIBITOR

      Clinical pharmacology and therapeutics
    92. GANDON JM; LECOZ F; KUHNE G; HUMPEL M; ALLAIN H
      PK PD INTERACTION STUDIES OF LISURIDE WITH ERYTHROMYCIN AND FOOD IN HEALTHY-VOLUNTEERS/

      Clinical pharmacology and therapeutics
    93. DELUMEAU JC; BENTUEFERRER D; GANDON JM; AMREIN R; BELLIARD S; ALLAIN H
      MONOAMINE-OXIDASE INHIBITORS, COGNITIVE FUNCTIONS AND NEURODEGENERATIVE DISEASES

      Journal of neural transmission. Supplementum
    94. ALLAIN H; WEANES K; NEUMAN E; GANDON JM; SALZMAN V; MALBEZIN M; GUEZ D
      ACCEPTABILITY AND CLINICAL ACTIVITY OF 4 WEEKS TREATMENT BY S12024-2 IN 53 INPATIENTS WITH MODERATE TO SEVERE ALZHEIMERS-DISEASE

      Neurobiology of aging
    95. SAIAG B; MILON D; BENTUEFERRER D; ALLAIN H; RAULT B; VANDENDRIESSCHE J
      INHIBITOR EFFECTS OF DILTIAZEM, NICARDIPINE, NIFEDIPINE AND VERAPAMILON THE NOREPINEPHRINE-INDUCED CONTRACTIONS OF THE CANINE SAPHENOUS-VEIN IN CALCIUM-FREE MEDIUM

      Research communications in chemical pathology and pharmacology
    96. BENTUEFERRER D; BELLISSANT E; DECOMBE R; ALLAIN H
      TEMPORAL PROFILE OF AMINERGIC NEUROTRANSMITTER RELEASE IN STRIATAL DIALYSATES IN RATS WITH POSTISCHEMIC SEIZURES

      Experimental Brain Research
    97. ALLAIN H; BELLIARD S; DECERTAINES J; BENTUEFERRER D; BUREAU M; LACROIX P
      POTENTIAL BIOLOGICAL TARGETS FOR ANTI-ALZHEIMER DRUGS

      Dementia
    98. ALLAIN H; POLLAK P; NEUKIRCH HC
      SYMPTOMATIC EFFECT OF SELEGILINE IN DE-NOVO PARKINSONIAN-PATIENTS

      Movement disorders
    99. DECOMBE R; BENTUEFERRER D; ALLAIN H; VANDENDRIESSCHE J
      ALTERATION OF AMINERGIC NEUROTRANSMITTER RELEASE AFTER 2 CONSECUTIVE TRANSIENT GLOBAL ISCHEMIAS - AN INVIVO MICRODIALYSIS STUDY IN RAT

      Neurological research
    100. ALLAIN H; RAOUL P; LIEURY A; LECOZ F; GANDON JM; DARBIGNY P
      EFFECT OF 2 DOSES OF GINKGO-BILOBA EXTRACT (EGB-761) ON THE DUAL-CODING TEST IN ELDERLY SUBJECTS

      Clinical therapeutics


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/05/20 alle ore 20:21:13